ReviewStem cell research2010
Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening.
Review in Stem cell research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Current hPSC-derived liver organoids for toxicity testing: Cytochrome P450 enzymes and drug metabolism.Toxicological research · 2025Review
- Unlocking the post-transplant microenvironment for successful islet function and survival.Frontiers in endocrinology · 2023Review
- Definition of germ layer cell lineage alternative splicing programs reveals a critical role for Quaking in specifying cardiac cell fate.Nucleic acids research · 2022Article
- Phenotypical, functional and transcriptomic comparison of two modified methods of hepatocyte differentiation from human induced pluripotent stem cells.Biomedical reports · 2022Article
- Liver organoids in domestic animals: an expected promise for metabolic studies.Veterinary research · 2021Review
- Amnion-Derived Mesenchymal Stromal/Stem Cell Paracrine Signals Potentiate Human Liver Organoid Differentiation: Translational Implications for Liver Regeneration.Frontiers in medicine · 2021Article
- Liver Organoids: Recent Developments, Limitations and Potential.Frontiers in medicine · 2021Review
- A Critical Perspective on 3D Liver Models for Drug Metabolism and Toxicology Studies.Frontiers in cell and developmental biology · 2021Review
- Prospects and Frontiers of Stem Cell Toxicology.Stem cells and development · 2017Review
- Paracrine signals regulate human liver organoid maturation from induced pluripotent stem cells.Development (Cambridge, England) · 2017Article
- Effects of Aminoglycoside Antibiotics on Human Embryonic Stem Cell Viability during Differentiation In Vitro.Stem cells international · 2017Article
- Article
- H3K27me3 Does Not Orchestrate the Expression of Lineage-Specific Markers in hESC-Derived Hepatocytes In Vitro.Stem cell reports · 2016Article
- Hepatic differentiation of human pluripotent stem cells in miniaturized format suitable for high-throughput screen.Stem cell research · 2016Article
- The Use of Induced Pluripotent Stem Cells for the Study and Treatment of Liver Diseases.Current protocols in toxicology · 2016Review
- One Standardized Differentiation Procedure Robustly Generates Homogenous Hepatocyte Cultures Displaying Metabolic Diversity from a Large Panel of Human Pluripotent Stem Cells.Stem cell reviews and reports · 2016Article
- MicroRNA-122: a novel hepatocyte-enriched in vitro marker of drug-induced cellular toxicity.Toxicological sciences : an official journal of the Society of Toxicology · 2015Article
- Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes.Journal of hepatology · 2015Article
- Immunomodulatory effects of transforming growth factor-β in the liver.Hepatobiliary surgery and nutrition · 2014Review
- Potential and Challenges of Induced Pluripotent Stem Cells in Liver Diseases Treatment.Journal of clinical medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hepatotoxicity is an enormous and increasing problem for the pharmaceutical industry. Early detection of problems during the drug discovery pathway is advantageous to minimize costs and improve patient safety. However, current cellular models are sub-optimal. This review addresses the potential use of pluripotent stem cells in the generation of hepatic cell lineages. It begins by highlighting the scale of the problem faced by the pharmaceutical industry, the precise nature of drug-induced liver injury and where in the drug discovery pathway the need for additional cell models arises. Current research is discussed, mainly for generating hepatocyte-like cells rather than other liver cell-types. In addition, an effort is made to identify where some of the major barriers remain in translating what is currently hypothesis-driven laboratory research into meaningful platform technologies for the pharmaceutical industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.